Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL314574

Clc1ccc(CCN2CCNCC2)cc1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 4/20 0.52
KDM4E B2RXH2 1/20 0.52
ALDH1A1 P00352 1/20 0.52
KCNH2 Q12809 2/20 0.50
KCNJ1 P48048 1/20 0.50
PRCP P42785 4/20 0.49
LMNA P02545 1/20 0.49
SLC2A1 P11166 1/20 0.48
EBP Q15125 1/20 0.46
SLC6A4 P31645 2/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
HTR2A P28223 1/20 0.45
THRB P10828 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3500303 0.85 SIGMAR1 (0.68) SIGMAR1KDM4EALDH1A1KCNH2KCNJ1
Hydrochloric Acid SCHEMBL14486498 0.84 SIGMAR1 (0.66) SIGMAR1KDM4EALDH1A1KCNH2KCNJ1
SCHEMBL10900445 0.80 KCNH2 (0.57) SIGMAR1KCNH2KCNJ1LMNASLC6A4
SCHEMBL5857488 0.77 KCNH2 (0.57) SIGMAR1KCNH2KCNJ1EBPSLC6A4
SCHEMBL10899595 0.77 KCNH2 (0.57) SIGMAR1ALDH1A1KCNH2KCNJ1SLC6A4
SCHEMBL9319743 0.76 SIGMAR1 (0.70) SIGMAR1KDM4EALDH1A1KCNH2KCNJ1
SCHEMBL9320154 0.75 SIGMAR1 (0.63) SIGMAR1KCNH2KCNJ1LMNASLC6A4
SCHEMBL5450696 0.75 KCNH2 (0.55) SIGMAR1KDM4EALDH1A1KCNH2KCNJ1
Trifluoroacetic Acid SCHEMBL22123107 0.75 KDM4E (0.39) SIGMAR1KDM4EALDH1A1LMNASLC2A1
Hydrochloric Acid SCHEMBL30152527 0.74 KCNH2 (0.54) SIGMAR1KDM4EALDH1A1KCNH2KCNJ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2234992-B1 PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2012-02-22 EP disclosed
US-8093248-B2 Compounds useful for the treatment of conditions associated with weight gain ASTRAZENECA AB (PUBL) (SE) 2012-01-10 US disclosed
EP-2234992-A2 PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS AstraZeneca AB (SE) 2010-10-06 EP disclosed
US-20090281087-A1 Compounds II BIOVITRUM AB (SE) 2009-11-12 US disclosed
WO-2009071668-A2 PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS BIOVITRUM AB (PUBL) (SE) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281087-A1 Compounds II GPR119, FABP4, LIPC SIGMAR1 2023/4885KDM4E 3606/4885ALDH1A1 2717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.